Liek používaný na alkoholizmus môže liečiť rakovinu zacielením na makrofágy
Výskumná skupina pod vedením Yuya Terashima z Tokijskej univerzity zistila, že liek používaný na alkoholizmus môže liečiť rakovina zacielením na makrofágy.
Podľa údajov WHO a Medzinárodnej agentúry pre výskum rakoviny (IARC) bolo v roku 18.1 9.6 milióna nových prípadov a 2018 milióna úmrtí. Každý piaty muž a jedna zo šiestich žien na celom svete počas svojho života dostane rakovinu a každý ôsmy muž a jedna z 5 žien na toto ochorenie zomrie. Na celom svete sa celkový počet ľudí, ktorí sú nažive do 6 rokov od diagnózy rakoviny, nazývaný 8-ročná prevalencia, odhaduje na 11 milióna.
Rakovina pľúc je najčastejším typom rakoviny u mužov (14.5 %) a hlavnou príčinou smrti u mužov (22 %). Po tomto nasleduje rakovina prostaty (13.5 %), kolorektálny karcinóm (10.9 %), & rakovina pečene (9.5 %). Medzi ženami, karcinóm prsníka je približne 25 %, nasleduje rakovina pľúc (13.8 %), kolorektálny karcinóm (9.5 %) a rakovina krčka maternice (6.6 %).
Building up a treatment to battle malignant growth remains one of the most troublesome difficulties in medicinal research. Malignant growth owes its infamous personality to the way that the disease cells utilize the host’s own resistant framework to develop and spread, finally getting savage. Invulnerable cells like macrophages, which usually battle to ensure ordinary cells, are commandeered by dangerous disease cells, and populate the earth around the tumors, turning out to be tumor-related macrophages (TAMs).
V skutočnosti sa zistilo, že zhubné tkanivo pacientov pre koho imunoterapia nebol plodný, bol v skutočnosti bohatý na makrofágy, čo potvrdzuje spojenie medzi chorobou a TAM. Sú to práve tieto TAM, ktoré produkujú označujúce proteíny, ako sú chemokíny, a spúšťajú inhibičné rezistentné kontrolné výboje, ktoré spôsobujú imunosupresiu. nádor condition, which ensures the malignant growth cells and permits their quickened development. Since the TAMs encourage the spreading of malignant rastové bunky, managing them as a remedial methodology for battling disease has picked up consideration as of late.
A research team from the Tokyo University of Science, under the direction of Yuya Terashima saw this as an opportunity to look into the field of developing new anti-malignant growth drugs. Their original work in Nature Immunology 2005 revealed the disclosure of another objective protein called FROUNT, which is connected to the guidelines and development of the TAMs. In this way, FROUNT was directly linked to TAM rules because it increased “chemokine signaling,” a type of cell communication that is necessary for TAM gathering and movement.
At that point, so as to diminish any symptoms, the group additionally built up an autonomous technique for restricting the impact of FROUNT on chemokine motion by repressing the connection between the two. The group screened 131,200 mixes and focused on disulfiram, a medication used to treat liquor abuse, and referred to for its potential as an enemy of malignant growth tranquilizer. This medication was found to legitimately tie to the FROUNT site, making FROUNT inaccessible for collaboration with the parts of chemokine flagging.
Considering the outcomes, Terashima clarifies, “When tried on mice, disulfiram repressed the development of macrophages and stifled the development of malignant growth cells. Thus, our findings reveal a new way to treat cancer that can stop the growth of cancer cells that are hard for immune systems to detect when used together with disulfiram.
Hopefully, we will get to see new therapies in the treatment of cancer.
